EP0276279A4 - Composition of matter and method of immunizing against viral causative agents of aids and arc. - Google Patents

Composition of matter and method of immunizing against viral causative agents of aids and arc.

Info

Publication number
EP0276279A4
EP0276279A4 EP19870905089 EP87905089A EP0276279A4 EP 0276279 A4 EP0276279 A4 EP 0276279A4 EP 19870905089 EP19870905089 EP 19870905089 EP 87905089 A EP87905089 A EP 87905089A EP 0276279 A4 EP0276279 A4 EP 0276279A4
Authority
EP
European Patent Office
Prior art keywords
aids
arc
matter
composition
against viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870905089
Other languages
German (de)
French (fr)
Other versions
EP0276279A1 (en
Inventor
Patrick Kanda
Ronald C Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Biomedical Research Institute
Original Assignee
Texas Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biomedical Research Institute filed Critical Texas Biomedical Research Institute
Publication of EP0276279A1 publication Critical patent/EP0276279A1/en
Publication of EP0276279A4 publication Critical patent/EP0276279A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19870905089 1986-07-21 1987-07-20 Composition of matter and method of immunizing against viral causative agents of aids and arc. Withdrawn EP0276279A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88874286A 1986-07-21 1986-07-21
US888742 2007-08-02

Publications (2)

Publication Number Publication Date
EP0276279A1 EP0276279A1 (en) 1988-08-03
EP0276279A4 true EP0276279A4 (en) 1990-01-08

Family

ID=25393799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870905089 Withdrawn EP0276279A4 (en) 1986-07-21 1987-07-20 Composition of matter and method of immunizing against viral causative agents of aids and arc.

Country Status (5)

Country Link
EP (1) EP0276279A4 (en)
JP (1) JPH01500432A (en)
AU (1) AU7786387A (en)
DK (1) DK149188A (en)
WO (1) WO1988000471A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
EP0255190A3 (en) * 1986-08-01 1990-08-29 Repligen Corporation Recombinant polypeptides and their uses, inclusing assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0362909A3 (en) * 1988-08-26 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies
EP0362910A3 (en) * 1988-08-27 1991-01-09 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
JPH04502760A (en) * 1988-10-03 1992-05-21 レプリゲン・コーポレーション Novel HIV proteins and peptides effective in the diagnosis, prevention and treatment of AIDS
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
EP0448095A1 (en) * 1990-03-21 1991-09-25 Wolf, Hans Joachim, Prof. Dr. Subregion of the retroviral ENV protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
FR2677654B1 (en) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
DE4417742A1 (en) 1994-05-20 1995-11-23 Bayer Ag Non-systemic control of parasites
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6659681B1 (en) 1999-02-10 2003-12-09 Traf Fix Devices, Inc. Laterally stable vertical panel system
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2458995C (en) 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CN106257728B (en) 2016-01-28 2018-01-12 中国科学院过程工程研究所 A kind of system and method for producing the high-purity V electrolyte of 3.5 valencys

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214709A2 (en) * 1985-09-11 1987-03-18 United Biomedical Inc. Synthetic peptide and process of using same for the detection of antibodies to HTLV-III, diagnosis of AIDS and pre-AIDS conditions and as a vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214709A2 (en) * 1985-09-11 1987-03-18 United Biomedical Inc. Synthetic peptide and process of using same for the detection of antibodies to HTLV-III, diagnosis of AIDS and pre-AIDS conditions and as a vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO8800471A1 *
The Journal of Biological Chemistry, Vol. 262, No. 12, April 25, 1987, pages 5768-5774, Baltimore, US; R.C. KENNEDY et al.: "Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope", whole article. *

Also Published As

Publication number Publication date
JPH01500432A (en) 1989-02-16
DK149188D0 (en) 1988-03-18
EP0276279A1 (en) 1988-08-03
DK149188A (en) 1988-05-06
AU7786387A (en) 1988-02-10
WO1988000471A1 (en) 1988-01-28

Similar Documents

Publication Publication Date Title
EP0276279A4 (en) Composition of matter and method of immunizing against viral causative agents of aids and arc.
GB8821049D0 (en) Method & composition for treatment & prevention of viral infections
PL268266A1 (en) The method of manufacture of proteins env virus aids
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
AU1952288A (en) Method of selectively inhibiting hiv
ZA906621B (en) Use of viruses against undesirable micro-organisms
AU1550983A (en) Blends of polyetherimide and organosiloxane-polycarbonate block copolymers
EP0283505A4 (en) Vaccine and method of preparation.
EP0232006A3 (en) Compositions for surface treatment, polymers therefor, and method of surface treatment
AU5064985A (en) Methods and compositions for treating viral infection
AR242561A1 (en) Procedure for the preparation of s-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride that is substantially pure, and the procedure involved.
OA08608A (en) Pestical compositions and process for preparation thereof.
EP0608212A4 (en) Method of treating viral infection.
EP0249611A4 (en) T-lymphotrophic virus.
EP0256608A3 (en) Method of preparation and use of solid, phytoactive compositions
ZA903258B (en) Method of suppressing hiv infection
EP0610444A4 (en) Method of treating viral diseases.
AU7515287A (en) Methods and compositions for treating viral infections
AU6796287A (en) Method and composition for prophylaxis and treatment of viral infections
ZA87470B (en) Method and composition for prophylaxis and treatment of viral infections
GB8614733D0 (en) Aids treatment
HUT44439A (en) Process for inhibiting the reproduction of viruses and virus infections
GB2197200B (en) Methods and compositions for gas deodorisation
OA09507A (en) Compositions and methods for treating or preventing AIDS ARC and HIV infection
GB8717955D0 (en) Prevention & treatment of aids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880321

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KANDA, PATRICK

Inventor name: KENNEDY, RONALD, C.

Inventor name: SPARROW, JAMES T.

A4 Supplementary search report drawn up and despatched

Effective date: 19900108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920201